MARKET

TGTX

TGTX

Tg Therapeutics Inc
NASDAQ
54.89
-0.12
-0.22%
After Hours: 54.75 -0.14 -0.25% 17:47 07/14 EDT
OPEN
55.57
PREV CLOSE
55.01
HIGH
55.87
LOW
54.80
VOLUME
2.03M
TURNOVER
--
52 WEEK HIGH
59.30
52 WEEK LOW
25.28
MARKET CAP
8.40B
P/E (TTM)
19.13
1D
5D
1M
3M
1Y
5Y
1D
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)
TipRanks · 7h ago
TG THERAPEUTICS INC <TGTX.O>: JP MORGAN RAISES TARGET PRICE TO $65 FROM $46
Reuters · 12h ago
TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
TipRanks · 1d ago
Weekly Report: what happened at TGTX last week (0706-0710)?
Weekly Report · 1d ago
TG Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
TG Therapeutics Price Target Raised to $77.00/Share From $70.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on TG Therapeutics, Raises Price Target to $77
Benzinga · 1d ago
TG Therapeutics Is Maintained at Underperform by B of A Securities
Dow Jones · 07/07 14:34
More
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.

Webull offers TG Therapeutics Inc stock information, including NASDAQ: TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.